371,629 Shares in Bausch Health Cos Inc. $BHC Acquired by Lido Advisors LLC

Lido Advisors LLC bought a new position in shares of Bausch Health Cos Inc. (NYSE:BHC) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 371,629 shares of the company’s stock, valued at approximately $2,583,000. Lido Advisors LLC owned about 0.10% of Bausch Health Cos at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Bausch Health Cos by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 12,241,072 shares of the company’s stock valued at $78,808,000 after buying an additional 470,968 shares in the last quarter. Goldentree Asset Management LP grew its holdings in Bausch Health Cos by 1.7% in the 3rd quarter. Goldentree Asset Management LP now owns 34,833,431 shares of the company’s stock valued at $224,409,000 after buying an additional 578,542 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new position in Bausch Health Cos in the 4th quarter valued at $3,651,000. Cinctive Capital Management LP acquired a new position in Bausch Health Cos in the 3rd quarter valued at $697,000. Finally, Private Management Group Inc. grew its holdings in Bausch Health Cos by 13.6% in the 3rd quarter. Private Management Group Inc. now owns 1,621,725 shares of the company’s stock valued at $10,460,000 after buying an additional 194,158 shares in the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BHC has been the topic of a number of research reports. Barclays decreased their price objective on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 25th. Wall Street Zen lowered Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 15th. Weiss Ratings lowered Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 4th. Finally, Royal Bank Of Canada decreased their price objective on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a report on Monday, April 27th. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bausch Health Cos has an average rating of “Reduce” and an average price target of $8.00.

Insider Activity

In other news, Director Frank D. Lee sold 24,456 shares of the stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total transaction of $132,796.08. Following the sale, the director directly owned 49,339 shares of the company’s stock, valued at approximately $267,910.77. This represents a 33.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 20.67% of the company’s stock.

Bausch Health Cos Stock Performance

BHC opened at $5.38 on Monday. The firm has a market cap of $2.01 billion, a P/E ratio of -1.66 and a beta of 0.40. Bausch Health Cos Inc. has a 52-week low of $4.67 and a 52-week high of $8.69. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32. The business’s fifty day moving average is $5.47 and its 200-day moving average is $6.02.

Bausch Health Cos (NYSE:BHC) last released its earnings results on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.03). The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.37 billion. Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%. Sell-side analysts expect that Bausch Health Cos Inc. will post 4.08 EPS for the current fiscal year.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.